Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 6/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.36 |
| ▸ | GAA | P10253 | 4/20 | 0.36 |
| ▸ | GLA | P06280 | 2/20 | 0.36 |
| ▸ | CASP1 | P29466 | 2/20 | 0.36 |
| ▸ | CASP7 | P55210 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MARK4 | Q96L34 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lingdolinurad SCHEMBL29673183 | 1.00 | ALDH1A1 (0.41) | ALDH1A1RXFP1MAPK1CYP1A2CYP2C9 | |
| Lingdolinurad SCHEMBL20377220 | 0.99 | ALDH1A1 (0.41) | ALDH1A1RXFP1MAPK1CYP1A2CYP2C9 | |
| Lingdolinurad SCHEMBL20377219 | 0.98 | ALDH1A1 (0.40) | ALDH1A1RXFP1MAPK1CYP1A2CYP2C9 | |
| SCHEMBL18629839 | 0.90 | MAPK1 (0.46) | ALDH1A1RXFP1MAPK1CYP1A2CYP2C9 | |
| SCHEMBL18629803 | 0.89 | ALDH1A1 (0.44) | ALDH1A1RXFP1MAPK1CYP1A2CYP2C9 | |
| SCHEMBL18629811 | 0.88 | ALDH1A1 (0.41) | ALDH1A1RXFP1MAPK1CYP1A2CYP2C9 | |
| SCHEMBL18629802 | 0.88 | ALDH1A1 (0.41) | ALDH1A1RXFP1MAPK1CYP1A2CYP2C9 | |
| SCHEMBL18629766 | 0.88 | ALDH1A1 (0.41) | ALDH1A1RXFP1MAPK1CYP1A2CYP2C9 | |
| Hydrochloric Acid SCHEMBL20377231 | 0.87 | ALDH1A1 (0.41) | ALDH1A1RXFP1MAPK1CYP1A2CYP2C9 | |
| Hydrochloric Acid SCHEMBL20377230 | 0.86 | ALDH1A1 (0.40) | ALDH1A1RXFP1MAPK1CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3915984-B1 | SYNTHESIS OF 3-BROMO-5-(2-ETHYLIMIDAZO[1,2-ALPHA]PYRIDINE-3-CARBONYL)-2-HYDROXYBENZONITRILE | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO LTD (CN) | 2024-10-30 | — | — | EP | claimed |
| CN-111410654-B | Synthesis of 3-bromo-5- (2-ethylimidazo [1,2-a ] pyridine-3-carbonyl) -2-hydroxybenzonitrile | 江苏新元素医药科技有限公司 | 2022-05-17 | — | — | CN | claimed |
| EP-3915984-A1 | SYNTHESIS OF 3-BROMO-5-(2-ETHYLIMIDAZO[1,2-alpha]PYRIDINE-3-CARBONYL)-2-HYDROXYBENZONITRILE | Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd. (CN) | 2021-12-01 | — | — | EP | claimed |
| WO-2020147803-A1 | SYNTHESIS OF 3-BROMO-5-(2-ETHYLIMIDAZO[1,2-α]PYRIDINE-3-CARBONYL)-2-HYDROXYBENZONITRILE | 江苏新元素医药科技有限公司 | 2020-07-23 | — | — | WO | claimed |
| CN-111410654-A | Synthesis of 3-bromo-5- (2-ethylimidazo [1,2-a ] pyridine-3-carbonyl) -2-hydroxybenzonitrile | 江苏新元素医药科技有限公司 | 2020-07-14 | — | — | CN | claimed |
| EP-3348557-B1 | IMIDAZO[1,2A]PYRIDINES FOR TREATING OR PREVENTING HYPERURICEMIA OR GOUT | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO LTD (CN) | 2020-04-29 | — | — | EP | claimed |
| US-10399971-B2 | Compound for treating or preventing hyperuricemia or gout | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2019-09-03 | — | — | US | claimed |
| US-20180282321-A1 | COMPOUND FOR TREATING OR PREVENTING HYPERURICEMIA OR GOUT | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2018-10-04 | — | — | US | claimed |
| EP-3348557-A1 | COMPOUND FOR TREATING OR PREVENTING HYPERURICEMIA OR GOUT | Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd (CN) | 2018-07-18 | — | — | EP | claimed |
| EP-3915984-B1 | SYNTHESIS OF 3-BROMO-5-(2-ETHYLIMIDAZO[1,2-ALPHA]PYRIDINE-3-CARBONYL)-2-HYDROXYBENZONITRILE | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO LTD (CN) | 2024-10-30 | — | — | EP | disclosed |
| US-RE50083-E1 | URAT1 inhibitor and use thereof | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2024-08-20 | — | — | US | disclosed |
| WO-2023221078-A1 | SOLID FORMS OF A COMPOUND FOR TREATING OR PREVENTING HYPERURICEMIA OR GOUT | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2023-11-23 | — | — | WO | disclosed |
| EP-3543240-B1 | URAT1 INHIBITOR AND USE THEREOF | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO LTD (CN) | 2022-07-06 | — | — | EP | disclosed |
| EP-3543240-B1 | URAT1 INHIBITOR AND USE THEREOF | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO LTD (CN) | 2022-07-06 | — | — | EP | disclosed |
| US-10399971-B2 | Compound for treating or preventing hyperuricemia or gout | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2019-09-03 | — | — | US | disclosed |
| US-20180282321-A1 | COMPOUND FOR TREATING OR PREVENTING HYPERURICEMIA OR GOUT | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2018-10-04 | — | — | US | disclosed |
| EP-3348557-A1 | COMPOUND FOR TREATING OR PREVENTING HYPERURICEMIA OR GOUT | Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd (CN) | 2018-07-18 | — | — | EP | disclosed |
| EP-3348557-A1 | COMPOUND FOR TREATING OR PREVENTING HYPERURICEMIA OR GOUT | Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd (CN) | 2018-07-18 | — | — | EP | disclosed |
| WO-2018090921-A1 | URAT1 INHIBITOR AND USE THEREOF | 江苏新元素医药科技有限公司 | 2018-05-24 | — | — | WO | disclosed |
| WO-2017041732-A1 | COMPOUND FOR TREATING OR PREVENTING HYPERURICEMIA OR GOUT | 江苏新元素医药科技有限公司 | 2017-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180282321-A1 | COMPOUND FOR TREATING OR PREVENTING HYPERURICEMIA OR GOUT | SLC10A1, SLC5A1, SLC10A6 | ALDH1A1 716/4885RXFP1 811/4885MAPK1 1142/4885 |
| US-10399971-B2 | Compound for treating or preventing hyperuricemia or gout | SLC10A1, SLC5A1, SLC10A6 | ALDH1A1 716/4885RXFP1 811/4885MAPK1 1142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.